主旨
伊马替尼
医学
间质细胞
间质瘤
甲磺酸伊马替尼
胃肠道
分子病理学
病理
癌症研究
生物信息学
肿瘤科
内科学
生物
遗传学
基因
髓系白血病
作者
Riccardo Ricci,Luca Saragoni
出处
期刊:PubMed
日期:2016-09-01
卷期号:108 (3): 90-103
被引量:2
摘要
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. The discovery of the occurrence of activating KIT mutations and KIT expression in GISTs opened the way to the unequivocal diagnosis of these tumors and to their successful treatment with imatinib, a tyrosin kinase inhibitor. Since then, research progress revealed molecular GIST triggers alternative to KIT, implying heterogeneous analytic approaches and prognostic expectations. Several targeted therapies, variably specific for each GIST trigger, have been developed or are being investigated. Thus, GISTs eventually revealed a family of diseases rather than a single tumor type. All these events had an unprecedented impact on pathology practice, constituting at the same time a heavy burden and an exciting challenge, ultimately putting pathologists in the spotlight as never before. This review will discuss the most recent advances concerning GISTs, highlighting the tasks of pathologists facing these tumors, with an emphasis on traps potentially compromising a correct diagnosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI